Top 10 healthcare challenges for 2019

Healthcare executives are facing a heap of challenges as technology speeds along and the industry continues to chug toward a value-based care system. Looking into 2019, executives see a lot of the same top challenges as they did in 2018, but digital healthcare and patient-centered care focused on total health are rising concerns, according to the latest rankings from Healthcare Executive Group, an industry network of executives.

The rankings take the pulse of evolving issues and concerns of executives in the field through an annual forum.

Here are the top 10 challenges for 2019 as identified by HCEG members:

  1. Data & analytics
  2. Total consumer health
  3. Population health services
  4. Value-based payments
  5. The digital healthcare organization
  6. Rising pharmacy costs
  7. External marketing disruption
  8. Operational effectiveness
  9. Opioid management
  10. Cybersecurity

Data and analytics were also in the top spot in 2018, marking the importance of leveraging data to manage health and drive clinical outcomes. Total consumer health, which focuses on improving overall medical, social, finance and environmental well-being of members rose to the No. 2 spot after coming in at fifth in 2018.

Population health services dropped just one slot from 2018 to 2019, and, like total consumer health, focus on a broader range of activities such as chronic care management, clinical integration and addressing barriers to care like social determinants.

Interestingly, cost transparency as a top concern fell off the 2019 list from 2018, though opioid management made its debut on the list. This may be reflective of the changing conversation around drug pricing and the mounting pressure for healthcare stakeholders and policymakers to address the growing opioid crisis.

The rankings were developed in partnership with Change Healthcare and have been published for the last seven years.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup